Intellia Therapeutics, Inc. (FRA:38I)

Market Cap	1.40B -38.3%
Revenue (ttm)	52.09M +12.6%
Net Income	-350.10M
EPS	-2.98
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,078
Open	9.72
Previous Close	10.10
Day's Range	9.62 - 9.80
52-Week Range	6.75 - 22.42
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 5, 2026

About Intellia Therapeutics

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis;...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 377
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 38I

Financial Performance

In 2025, Intellia Therapeutics's revenue was $67.67 million, an increase of 16.92% compared to the previous year's $57.88 million. Losses were -$412.69 million, -20.49% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error